Een studie om te bepalen of BHV-8000 effectief, veilig en aanvaardbaar is als een behandeling voor volwassenen die leven met de vroege ziekte van Parkinson
Een fase 2/3, dubbelblinde, placebo-gecontroleerde studie van BHV-8000 bij deelnemers met de vroege ziekte van Parkinson
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Chief Medical Officer
- Telefoonnummer: 203-404-0410
- E-mail: clinicaltrials@biohavenpharma.com
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- Werving
- Site-049
-
-
Arizona
-
Sun City, Arizona, Verenigde Staten, 85351
- Werving
- Site-079
-
-
California
-
Irvine, California, Verenigde Staten, 92618
- Werving
- Site-003
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- Site-041
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- Site-025
-
-
Connecticut
-
Farmington, Connecticut, Verenigde Staten, 06030
- Werving
- Site-031
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Site-028
-
-
Florida
-
Atlantis, Florida, Verenigde Staten, 33462
- Werving
- Site-038
-
Boca Raton, Florida, Verenigde Staten, 33486
- Werving
- Site-017
-
Maitland, Florida, Verenigde Staten, 32751
- Werving
- Site-051
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Site-027
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- Site-029
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Site-071
-
Foxborough, Massachusetts, Verenigde Staten, 02035
- Werving
- Site-004
-
-
Michigan
-
Farmington Hills, Michigan, Verenigde Staten, 48334
- Werving
- Site-015
-
-
Missouri
-
Chesterfield, Missouri, Verenigde Staten, 63005
- Werving
- Site-044
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Werving
- Site-006
-
New York, New York, Verenigde Staten, 10021
- Werving
- Site-005
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- Site-082
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97210
- Werving
- Site-091
-
-
Texas
-
Round Rock, Texas, Verenigde Staten, 78681
- Werving
- Site-043
-
-
Virginia
-
Henrico, Virginia, Verenigde Staten, 23233
- Werving
- Site-009
-
Newport News, Virginia, Verenigde Staten, 23601
- Werving
- Site-074
-
-
Washington
-
Bellevue, Washington, Verenigde Staten, 98007
- Werving
- Site-007
-
Seattle, Washington, Verenigde Staten, 98122
- Werving
- Site-019
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent.
- Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator.
- Have a clinician-documented diagnosis of idiopathic PD with an onset within 2 years of the Screening Visit
Key Exclusion Criteria:
- Medical history indicating a Parkinsonian syndrome other than idiopathic PD, including, but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia.
- Diagnosis of clinically significant central nervous system (CNS) disease other than PD.
- Participants who are current smokers (defined as smoking [in any form, e.g., tobacco smoke, electronic cigarettes, etc.] )
- Treatment with PD medication(s)
- Any other condition(s) that may compromise participant safety, interfere with study conduct, or jeopardize the potential proper interpretation of study results, in the opinion of the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: BHV-8000 10 mg
Double-blind (DB) Phase (Randomization through Week 48): Participants will receive blinded IP. Open-label Phase: Participants will receive BHV-8000. |
taken orally taken orally taken orally |
|
Experimenteel: BHV-8000 20 mg
Double-blind (DB) Phase (Randomization through Week 48): Participants will receive blinded IP. Open-label Phase: Participants will receive BHV-8000. |
taken orally taken orally taken orally |
|
Placebo-vergelijker: Placebo
Double-blind (DB) Phase (Randomization through Week 48): Participants will receive blinded IP (matching placebo). Open-label Phase: Participants will receive BHV-8000. |
taken orally taken orally taken orally |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to first qualifying worsening event on Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II
Tijdsspanne: Up to 48 Weeks
|
To evaluate the efficacy of BHV-8000 compared to placebo. This objective is measured by assessing the time to prespecified worsening on MDS-UPDRS Part II (motor experiences of daily living per self-administered questionnaire). MDS-UPDRS Part II is a 52-point scale with a higher total score representing more severe disability. |
Up to 48 Weeks
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III from Baseline to Week 48 of the DB Phase
Tijdsspanne: Baseline to Week 48
|
To evaluate the efficacy of BHV-8000 compared to placebo. This objective is measured by assessing the change in MDS-UPDRS Part III (motor examination conducted by rater). MDS-UPDRS Part III is a 132-point scale with a higher total score representing a greater degree of motor impairment. |
Baseline to Week 48
|
|
Change in Clinical Global Impression of Severity (CGI-S) from Baseline to Week 48 of the DB Phase
Tijdsspanne: Baseline to Week 48
|
To evaluate the efficacy of BHV-8000 compared to placebo. This objective is measured by assessing the change in severity of a participant's illness as determined by the managing clinician. The CGI-S is a 7-point scale (1 - 7) with 7 representing the most extremely ill participants. |
Baseline to Week 48
|
|
Change in DaT-SPECT scan from Baseline to Week 48 of the DB Phase
Tijdsspanne: Baseline to Week 48
|
To evaluate the efficacy of BHV-8000 compared to placebo. This objective is measured by change in DaT-SPECT Striatal Binding Ratio (SBR) in the putamen (assessing the activity of the dopamine transporters). Reduced uptake of the radiotracer is indicative of a decreased number of dopamine-secreting cells and suggestive of disease progression. |
Baseline to Week 48
|
|
Change in Parkinson's Disease Composite Score - Function (PARCOMS-Function) from Baseline to Week 48 of the DB Phase
Tijdsspanne: Baseline to Week 48
|
To compare the efficacy of BHV-8000 compared to placebo. This objective is measured by changes in the Parkinson's Disease Composite Score - Function (PARCOMS-Function) score. The PARCOMS-Function is a composite of select items taken from the MDS-UPDRS Part II and the PDQ-39© (assessing ability to complete daily activities). The PARCOMS-Function is a 100-point scale (0 - 100) with higher scores representing greater dysfunction. |
Baseline to Week 48
|
|
Number of Participants with Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
Tijdsspanne: Up to 96 weeks
|
To assess the safety and tolerability of BHV-8000. This objective will be measured by assessing the number of unique participants with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs |
Up to 96 weeks
|
|
Number of participants with clinically significant laboratory abnormalities
Tijdsspanne: Up to 96 weeks
|
To assess the safety and tolerability of BHV-8000. This objective will be measured by assessing the number of unique participants with treatment-emergent Grade 3 and 4 laboratory abnormalities |
Up to 96 weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- BHV8000-301
- 2025-521113-13-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .